S W Parry1, N Steen, R S Bexton, M Tynan, R A Kenny. 1. Falls and Syncope Service, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, UK. swparry@hotmail.com
Abstract
OBJECTIVES: While carotid sinus syndrome (CSS) is traditionally defined by the association of carotid sinus hypersensitivity (CSH) with syncope, uncertainty remains over the role, if any, of complex pacing in patients with CSH and unexplained or recurrent falls. We sought to clarify the role of dual chamber pacing in this patient group in the first placebo-controlled study in CSH. DESIGN: Randomised, double-blind, crossover, placebo-controlled trial. SETTING: Specialist falls and syncope facility. PATIENTS: Consecutive subjects aged over 55 years with CSH as the sole attributable cause of three or more unexplained falls in the 6 months preceding enrolment. INTERVENTION: Dual-chamber permanent pacing with rate-drop response programming. The pacemaker was switched on (DDD/RDR) or off (ODO (placebo)) for 6 months, then crossed over to the alternate mode for a further 6 months, in randomised, double-blind fashion. MAIN OUTCOME MEASURE: The primary outcome measure was number of falls in paced and non-paced modes. RESULTS:Twenty-five of 34 subjects (mean 76.8 years (SD 9.0), 27 (79%) female) recruited completed the study. Pacing intervention had no effect on number of falls (4.04 (9.54) in DDD/RDR mode, 3.48 (7.22) in ODO; relative risk of falling in ODO mode 0.82, 95% CI 0.62 to 1.10). CONCLUSION:Permanent pacing intervention had no effect on fall rates in older patients with CSH. Further work is urgently needed to clarify the role, if any, of complex pacing in this patient group.
RCT Entities:
OBJECTIVES: While carotid sinus syndrome (CSS) is traditionally defined by the association of carotid sinus hypersensitivity (CSH) with syncope, uncertainty remains over the role, if any, of complex pacing in patients with CSH and unexplained or recurrent falls. We sought to clarify the role of dual chamber pacing in this patient group in the first placebo-controlled study in CSH. DESIGN: Randomised, double-blind, crossover, placebo-controlled trial. SETTING: Specialist falls and syncope facility. PATIENTS: Consecutive subjects aged over 55 years with CSH as the sole attributable cause of three or more unexplained falls in the 6 months preceding enrolment. INTERVENTION: Dual-chamber permanent pacing with rate-drop response programming. The pacemaker was switched on (DDD/RDR) or off (ODO (placebo)) for 6 months, then crossed over to the alternate mode for a further 6 months, in randomised, double-blind fashion. MAIN OUTCOME MEASURE: The primary outcome measure was number of falls in paced and non-paced modes. RESULTS: Twenty-five of 34 subjects (mean 76.8 years (SD 9.0), 27 (79%) female) recruited completed the study. Pacing intervention had no effect on number of falls (4.04 (9.54) in DDD/RDR mode, 3.48 (7.22) in ODO; relative risk of falling in ODO mode 0.82, 95% CI 0.62 to 1.10). CONCLUSION: Permanent pacing intervention had no effect on fall rates in older patients with CSH. Further work is urgently needed to clarify the role, if any, of complex pacing in this patient group.
Authors: Lesley D Gillespie; M Clare Robertson; William J Gillespie; Catherine Sherrington; Simon Gates; Lindy M Clemson; Sarah E Lamb Journal: Cochrane Database Syst Rev Date: 2012-09-12
Authors: Lucas Lauder; Bruno R da Costa; Sebastian Ewen; Sean S Scholz; William Wijns; Thomas F Lüscher; Patrick W Serruys; Elazer R Edelman; Davide Capodanno; Michael Böhm; Peter Jüni; Felix Mahfoud Journal: Eur Heart J Date: 2020-07-14 Impact factor: 35.855
Authors: Steve W Parry; Vincent Deary; Tracy Finch; Claire Bamford; Neil Sabin; Peter McMeekin; John O'Brien; Alma Caldwell; Nick Steen; Susan L Whitney; Claire Macdonald; Elaine McColl Journal: Trials Date: 2014-06-06 Impact factor: 2.279
Authors: Nazmi Krasniqi; Diana Segalada; Thomas F Lüscher; Kurt Lippuner; Laurent Haegeli; Jan Steffel; Thomas Wolber; Corinna Brunckhorst; Johannes Holzmeister; David Hürlimann; Firat Duru Journal: Cardiol Res Pract Date: 2012-10-24 Impact factor: 1.866